Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 22:18:17562848251326471.
doi: 10.1177/17562848251326471. eCollection 2025.

Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's disease

Pauline Wils  1   2 , Mathurin Fumery  3 , Maria Nachury  1   2 , Clara Yzet  3 , Dilek Coban  4 , Anthony Buisson  4   5
Affiliations

Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn's disease

Pauline Wils et al. Therap Adv Gastroenterol. .

Abstract

Background and objectives: We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn's disease (CD).

Design: Subgroup analysis of REMSWITCH studies.

Methods: We described the clinical and MRI outcomes of patients with a prior or current CD perianal lesions after the switch.

Results: In REMSWITCH, 40 CD patients had a prior history of perianal lesions. No patient experienced a new perianal lesion (median follow-up = 18 months). Among the three patients (3/40, 7.5%) with clinically active perianal lesions at baseline, two patients had no more perianal lesions at month 18 while the last patient experienced lesions worsening. Another one with active perianal lesions on MRI but no symptom at baseline did not have any relapse within 18 months. Only one patient (1/40, 2.5%) had a perianal relapse (at month 25) with remission recapture after SC infliximab intensification.

Conclusion: Switching from IV to SC infliximab in CD with perianal lesions is safe and feasible.

Keywords: Crohn’s disease; infliximab; perianal lesions; subcutaneous; switch.

Plain language summary

Reassuring data on switching from IV to SC infliximab therapy in patients with perianal Crohn’s disease In this sub-analysis of the REMSWITCH study, patients with prior history of Crohn’s disease perianal lesions had reassuring evolution after switching from IV to SC infliximab. A prior history of perianal lesions should not prevent this switch in daily practice.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Rate of patients in perianal clinical remission (a) and evolution of perianal Crohn’s disease (b) after switching from IV to SC infliximab. IV, intravenous; SC, subcutaneous.
See this image and copyright information in PMC

References

    1. Buisson A, Nachury M, Reymond M, et al.. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol 2023; 21: P2338–P2346. - PubMed
    1. Buisson A, Nachury M, Bazoge M, et al.. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study. Aliment Pharmacol Ther 2024; 59: 526–534. - PubMed
    1. Sandborn WJ, Fazio VW, Feagan BG, et al.. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003; 125: 1508–1530. - PubMed
    1. Maaser C, Sturm A, Vavricka SR, et al.. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019; 13: 144–164K. - PubMed
    1. Chetwood JD, Tran Y, Subramanian S, et al.. Intravenous versus subcutaneous infliximab in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2024; 18(9): 1440–1449. - PubMed

LinkOut - more resources